Fate Therapeutics, Inc. Profile Avatar - Palmy Investing

Fate Therapeutics, Inc.

Fate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops programmed cellular immunotherapies for cancer and immune disorders worldwide. Its NK- and T-cell immuno-oncology programs under development include FT516 for the treatment of …

Biotechnology
US, San Diego [HQ]
Financials

Analysts

Reported
Past Estimate Consensus
Future Estimate Consensus
Fate Therapeutics, Inc. can't present any analysts estimates at the moment detail analysis.
End of FATE's Analysis
CIK: 1434316 CUSIP: 31189P102 ISIN: US31189P1021 LEI: - UEI: -
Secondary Listings
FATE has no secondary listings inside our databases.